CY1123742T1 - Τριτερπενοειδη με ανασταλτικη δραστικοτητα ωριμανσης hiv, υποκατεστημενα στη θεση 3 με μη-αρωματικο δακτυλιο που φερει αλογονοαλκυλ υποκαταστατη - Google Patents
Τριτερπενοειδη με ανασταλτικη δραστικοτητα ωριμανσης hiv, υποκατεστημενα στη θεση 3 με μη-αρωματικο δακτυλιο που φερει αλογονοαλκυλ υποκαταστατηInfo
- Publication number
- CY1123742T1 CY1123742T1 CY20201101017T CY201101017T CY1123742T1 CY 1123742 T1 CY1123742 T1 CY 1123742T1 CY 20201101017 T CY20201101017 T CY 20201101017T CY 201101017 T CY201101017 T CY 201101017T CY 1123742 T1 CY1123742 T1 CY 1123742T1
- Authority
- CY
- Cyprus
- Prior art keywords
- triterpenoids
- substituted
- halogonalkyl
- substituent
- aromatic ring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Abstract
Ενώσεις που έχουν φαρμάκου και βιο-επηρεασμού ιδιότητες, φαρμακευτικές συνθέσεις αυτών και μέθοδοι χρήσης εκτίθενται. Ιδιαιτέρως, τριτερπενοειδή που κατέχουν μοναδική αντι-ιική δραστικότητα παρέχονται ως αναστολείς ωρίμανσης HIV, όπως αντιπροσωπεύεται με ενώσεις του Τύπου Ι: με Χ επιλεγόμενο από C4-8 κυκλοαλκύλ, C4-8 κυκλοαλκενύλ, C4-9 σπειροκυκλοαλκύλ, C4-9 σπειροκυκλοαλκενύλ, C4-8 οξακυκλοαλκύλ, C4-8 διοξακυκλοαλκύλ, C6-8 οξακυκλοαλκενύλ, C6-8 διοξακυκλοαλκενύλ, C6 κυκλοδιαλκενύλ, C6 οξακυκλοδιαλκενύλ, C6-9 οξασπειροκυκλοαλκύλ και C6-9 οξασπειροκυκλοαλκενύλ δακτύλιο, έτσι ώστε Χ είναι υποκατεστημένη με Α, όπου Α είναι -C1-6 αλκυλ- αλογόνο. Αυτές οι ενώσεις είναι χρήσιμες για τη θεραπεία HIV και AIDS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978306P | 2014-04-11 | 2014-04-11 | |
| PCT/US2015/025029 WO2015157483A1 (en) | 2014-04-11 | 2015-04-09 | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123742T1 true CY1123742T1 (el) | 2022-03-24 |
Family
ID=53002809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101017T CY1123742T1 (el) | 2014-04-11 | 2020-10-27 | Τριτερπενοειδη με ανασταλτικη δραστικοτητα ωριμανσης hiv, υποκατεστημενα στη θεση 3 με μη-αρωματικο δακτυλιο που φερει αλογονοαλκυλ υποκαταστατη |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US9527882B2 (el) |
| EP (2) | EP3129392B1 (el) |
| JP (1) | JP6568202B2 (el) |
| KR (1) | KR102411082B1 (el) |
| CN (1) | CN106604909B (el) |
| AR (1) | AR101077A1 (el) |
| AU (1) | AU2015243500B2 (el) |
| BR (1) | BR112016023414B1 (el) |
| CA (1) | CA2944778C (el) |
| CL (1) | CL2016002528A1 (el) |
| CR (1) | CR20160472A (el) |
| CY (1) | CY1123742T1 (el) |
| DK (1) | DK3129392T3 (el) |
| DO (1) | DOP2016000277A (el) |
| EA (1) | EA030178B1 (el) |
| ES (1) | ES2828705T3 (el) |
| HR (1) | HRP20201645T1 (el) |
| HU (1) | HUE051719T2 (el) |
| IL (1) | IL248053B (el) |
| LT (1) | LT3129392T (el) |
| MA (1) | MA39374A1 (el) |
| MX (1) | MX2016013425A (el) |
| NZ (1) | NZ724644A (el) |
| PE (1) | PE20161391A1 (el) |
| PH (1) | PH12016501951A1 (el) |
| PL (1) | PL3129392T3 (el) |
| PT (1) | PT3129392T (el) |
| RS (1) | RS60959B1 (el) |
| SG (2) | SG11201608041QA (el) |
| SI (1) | SI3129392T1 (el) |
| TW (1) | TWI659964B (el) |
| UA (1) | UA120927C2 (el) |
| UY (1) | UY36070A (el) |
| WO (1) | WO2015157483A1 (el) |
| ZA (1) | ZA201606748B (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ724644A (en) | 2014-04-11 | 2023-07-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| BR112018010163A2 (pt) * | 2015-11-20 | 2018-11-21 | Viiv Healthcare Uk No 4 Ltd | formulação, e, método para tratamento de infecção por hiv |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3506902A4 (en) * | 2016-08-31 | 2020-04-22 | VIIV Healthcare Company | COMBINATIONS AND USES AND TREATMENTS THEREOF |
| PT3784349T (pt) | 2018-04-24 | 2024-01-22 | Viiv Healthcare Uk No 5 Ltd | Compostos com atividade inibidora de maturação do hiv |
| WO2020121161A1 (en) | 2018-12-10 | 2020-06-18 | ViiV Healthcare UK (No.4) Limited | Mesylate salt of an amino-lupane compound with hiv maturation inhibitory activity |
| CN109705189B (zh) * | 2018-12-29 | 2020-06-05 | 中国医学科学院药用植物研究所 | 具有式i所示结构的三萜衍生物及其制备方法和应用 |
| CN110981765A (zh) * | 2019-11-07 | 2020-04-10 | 肇庆巨元生化有限公司 | 一种25-羟基维生素d3中间体的制备方法 |
| WO2021116872A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4906661A (en) | 1981-11-12 | 1990-03-06 | E. I. Du Pont De Nemours And Company | Esters of aryloxypropanolamine derivatives |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| AR035311A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| CA2560266A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US20090105203A1 (en) | 2006-10-16 | 2009-04-23 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| EP2178376A4 (en) * | 2007-08-03 | 2011-12-14 | Advanced Life Sciences Inc | LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG |
| WO2009100532A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | NOVEL 17ß LUPANE DERIVATIVES |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| CN103038245B (zh) * | 2010-06-04 | 2015-03-25 | 百时美施贵宝公司 | 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物 |
| RS54239B1 (en) | 2010-06-04 | 2015-12-31 | Bristol-Myers Squibb Company | C-28 MODIFIED C-3 BETULINIC ACID DERIVATIVES AS INHIBITORS OF HIV AGING |
| KR101886467B1 (ko) | 2011-01-31 | 2018-08-07 | 비브 헬스케어 유케이 (넘버4) 리미티드 | Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드 |
| JP6000283B2 (ja) | 2011-01-31 | 2016-09-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| NZ724644A (en) | 2014-04-11 | 2023-07-28 | Viiv Healthcare Uk No 4 Ltd | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
-
2015
- 2015-04-09 NZ NZ724644A patent/NZ724644A/en unknown
- 2015-04-09 PL PL15718402T patent/PL3129392T3/pl unknown
- 2015-04-09 EP EP15718402.9A patent/EP3129392B1/en active Active
- 2015-04-09 KR KR1020167031312A patent/KR102411082B1/ko active IP Right Grant
- 2015-04-09 CA CA2944778A patent/CA2944778C/en active Active
- 2015-04-09 DK DK15718402.9T patent/DK3129392T3/da active
- 2015-04-09 CN CN201580031487.2A patent/CN106604909B/zh active Active
- 2015-04-09 US US14/682,179 patent/US9527882B2/en active Active
- 2015-04-09 EA EA201691760A patent/EA030178B1/ru unknown
- 2015-04-09 MX MX2016013425A patent/MX2016013425A/es active IP Right Grant
- 2015-04-09 PE PE2016001948A patent/PE20161391A1/es unknown
- 2015-04-09 JP JP2017504607A patent/JP6568202B2/ja active Active
- 2015-04-09 AR ARP150101078A patent/AR101077A1/es unknown
- 2015-04-09 HU HUE15718402A patent/HUE051719T2/hu unknown
- 2015-04-09 BR BR112016023414-6A patent/BR112016023414B1/pt active IP Right Grant
- 2015-04-09 SG SG11201608041QA patent/SG11201608041QA/en unknown
- 2015-04-09 CR CR20160472A patent/CR20160472A/es unknown
- 2015-04-09 RS RS20201276A patent/RS60959B1/sr unknown
- 2015-04-09 SG SG10201709017PA patent/SG10201709017PA/en unknown
- 2015-04-09 TW TW104111466A patent/TWI659964B/zh active
- 2015-04-09 EP EP20187878.2A patent/EP3750910A1/en active Pending
- 2015-04-09 ES ES15718402T patent/ES2828705T3/es active Active
- 2015-04-09 UY UY0001036070A patent/UY36070A/es not_active Application Discontinuation
- 2015-04-09 AU AU2015243500A patent/AU2015243500B2/en active Active
- 2015-04-09 UA UAA201609970A patent/UA120927C2/uk unknown
- 2015-04-09 SI SI201531396T patent/SI3129392T1/sl unknown
- 2015-04-09 WO PCT/US2015/025029 patent/WO2015157483A1/en active Application Filing
- 2015-04-09 LT LTEP15718402.9T patent/LT3129392T/lt unknown
- 2015-04-09 PT PT157184029T patent/PT3129392T/pt unknown
- 2015-04-09 MA MA39374A patent/MA39374A1/fr unknown
-
2016
- 2016-09-26 IL IL248053A patent/IL248053B/en active IP Right Grant
- 2016-09-29 ZA ZA2016/06748A patent/ZA201606748B/en unknown
- 2016-10-03 PH PH12016501951A patent/PH12016501951A1/en unknown
- 2016-10-05 CL CL2016002528A patent/CL2016002528A1/es unknown
- 2016-10-11 DO DO2016000277A patent/DOP2016000277A/es unknown
- 2016-11-07 US US15/344,756 patent/US20170056420A1/en not_active Abandoned
-
2017
- 2017-08-16 US US15/678,381 patent/US10245275B2/en active Active
-
2019
- 2019-01-22 US US16/253,393 patent/US10780102B2/en active Active
-
2020
- 2020-08-03 US US16/983,052 patent/US11464790B2/en active Active
- 2020-10-13 HR HRP20201645TT patent/HRP20201645T1/hr unknown
- 2020-10-27 CY CY20201101017T patent/CY1123742T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123742T1 (el) | Τριτερπενοειδη με ανασταλτικη δραστικοτητα ωριμανσης hiv, υποκατεστημενα στη θεση 3 με μη-αρωματικο δακτυλιο που φερει αλογονοαλκυλ υποκαταστατη | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1119544T1 (el) | Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv | |
| CY1122246T1 (el) | Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων | |
| CY1122534T1 (el) | Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 | |
| CY1120834T1 (el) | Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1 | |
| CY1124638T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων | |
| CY1124222T1 (el) | Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CY1122012T1 (el) | Ενωσεις ως ρυθμιστες του ror γαμμα | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| CY1119545T1 (el) | Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv | |
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| CY1122916T1 (el) | Νεες ενωσεις ως ρυθμιστες ror γαμμα | |
| CY1121480T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν δοτες νιτροξυλιου | |
| PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
| CU24525B1 (es) | Derivado de quinoleína para tratar y prevenir infecciones virales | |
| CY1124450T1 (el) | Νουκλεοτιδια βητα-νικοτινικου εστερα και διεργασιες για την παρασκευη αυτων | |
| CY1123582T1 (el) | Προφαρμακα των αναστολεων αντιστροφης μεταγραφασης hiv | |
| CY1123574T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων | |
| CY1120607T1 (el) | Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| CY1121693T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
| WO2016178092A8 (en) | C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors |